Press Releases

Switzerland first country to launch Xultophy® (IDegLira) (19 Jan 2015)

Tresiba® receives positive opinion from CHMP for treatment of children with diabetes (19 Dec 2014)

New Xultophy® (IDegLira) data show rapid and predictable glycaemic improvements in people with type 2 diabetes (19 Sep 2014)

Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen (18 Sep 2014)

New data show long-term efficacy and safety of Tresiba® in children and adolescents with type 1 diabetes (16 Sep 2014)

Mexico first country to launch Ryzodeg® (1 Sep 2014)

Novo Nordisk accepts fine for violating disclosure obligation in Denmark (18 Aug 2014)

New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes (14 Jun 2014)

Novo Nordisk to present 63 abstracts at 74th Annual American Diabetes Association Scientific Sessions in San Francisco, CA (10 Jun 2014)

Tresiba® and Victoza® receive positive opinions from CHMP for label updates expanding indications for use in adults with type 2 diabetes (21 Mar 2014)

Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation (10 Dec 2013)

Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes1 (3 Dec 2013)

IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin* (3 Dec 2013)

IDegLira improves glycaemic control throughout the day with no weight gain and a low rate of hypoglycaemia* (27 Sep 2013)

New study demonstrates efficacy throughout 2.5 years for Tresiba® (24 Sep 2013)

Study confirms improved health-related quality of life for patients with type 2 diabetes receiving Tresiba® (22 Jun 2013)

Novo Nordisk lancerer Tresiba® (insulin degludec) i Danmark (4 Mar 2013)

Tresiba® now ready to be launched in Japan (13 Feb 2013)

Novo Nordisk upgraded to ‘A1’ by Moody’s (5 Dec 2012)

Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia than insulin glargine in a 2-year study investigating 1,030 people with type 2 diabetes who had not previously used insulin (2 Oct 2012)

Investigational ultra-long-acting insulin degludec reduces rates of nocturnal hypoglycaemia in type 2 diabetes patients versus insulin glargine (9 Jun 2012)

Data show that the combination insulin degludec/insulin aspart significantly reduced hypoglycaemia in type 1 and type 2 diabetes patients (6 Dec 2011)

Data show that ultra-long-acting insulin degludec can be flexibly dosed at any time of the day in people with type 2 diabetes (14 Sep 2011)

Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control in patients with type 1 and type 2 diabetes (27 Jun 2011)

Phase 2 data for ultra-long-acting insulin degludec show the potential to effectively lower blood sugar, including when used three times a week (26 Jun 2010)

Search for Danish versions and earlier news releases:

Search for:


Sign up for the latest news from Novo Nordisk




RSS feeds

Click here to go to the download centre to download presenations, reports or magazines